**ARUP LABORATORIES | aruplab.com**
500 Chipeta Way, Salt Lake City, Utah 84108-1221
phone: 801-583-2787, toll free: 800-522-2787
Tracy I. George, MD, Chief Medical Officer

Patient Report

Patient Age/Sex: Male

**Specimen Collected: 13-Jun-22 14:49**

**Fungal Antibodies with Reflex, CSF** | **Received: 13-Jun-22 14:53** | **Report/Verified: 13-Jun-22 15:18**

| Procedure | Result | Units | Reference Interval |
|---|---|---|---|
| Coccidioides Ab by CF, CSF | **1:8** * i1 | | <1:2 |
| Histoplasma M,CSF (CF) | **1:8** * i2 | | <1:2 |
| Histoplasma Y,CSF (CF) | **1:16** * i3 | | <1:2 |
| Aspergillus Antibody, CSF (CF) | **1:32** * i4 | | <1:2 |
| Blastomyces Antibodies EIA,CSF | **2.0** H f1 i5 | IV | <=0.9 |

**Blastomyces Ab by Immunodiffusion, CSF** | **Received: 13-Jun-22 14:53** | **Report/Verified: 13-Jun-22 15:19**

| Procedure | Result | Units | Reference Interval |
|---|---|---|---|
| Blastomyces Antibodies by ID,CSF | **Detected** * f2 i6 | | Not Detected |

## Result Footnote

f1: Blastomyces Antibodies EIA, CSF

Blastomyces antibodies are elevated, Blastomyces by Immunodiffusion will be performed. An elevated Blastomyces EIA result in combination with a None Detected Immunodiffusion result may indicate either early infection or a falsely elevated EIA result. Repeat testing in 10 - 14 days may help clarify the diagnosis.

f2: Blastomyces Antibodies by ID, CSF

Blastomyces antibodies were detected, suggesting recent or active infection.

## Test Information

i1: Coccidioides Ab by CF, CSF

INTERPRETIVE INFORMATION: Coccidioides Ab by Complement Fixation (CF)

Any titer suggests past or current infection. However, greater than 30 percent of cases with chronic residual pulmonary disease have negative Complement Fixation (CF) tests. Titers of less than 1:32 (even as low as 1:2) may indicate past infection or self-limited disease; anticoccidiodal CF antibody titers in excess of 1:16 may indicate disseminated infection. CF serology may be used to follow therapy. Antibody in CSF is considered diagnostic for coccidioidal meningitis, although 10 percent of patients with coccidioidal meningitis will not have antibody in CSF.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

i2: Histoplasma M, CSF (CF)

INTERPRETIVE INFORMATION: Histoplasma M, CSF (CF)

## Test Information

i2: Histoplasma M, CSF (CF)

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

i3: Histoplasma Y, CSF (CF)

INTERPRETIVE INFORMATION: Histoplasma Y, CSF (CF)

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

i4: Aspergillus Antibody, CSF (CF)

INTERPRETIVE INFORMATION: Aspergillus Antibody, CSF (CF)

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

i5: Blastomyces Antibodies EIA, CSF

INTERPRETIVE INFORMATION: Blastomyces Antibodies EIA, CSF

0.9 IV or less.....Negative
1.0-1.4 IV.....Equivocal
1.5 IV or greater....Positive

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

i6: Blastomyces Antibodies by ID, CSF

INTERPRETIVE INFORMATION: Blastomyces Ab by Immunodiffusion, CSF

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.